GLPG Galapagos NV gains 23% Sep 21, 2017

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The company is developing filgotinib, which has completed Phase 2 clinical trial for the treatment of rheumatoid arthritis and Crohn's disease; GLPG1837, which is in Phase 2 clinical program, as well as GLPG2222, which is in Phase 1 clinical trial for treatment of cystic fibrosis mutations; and GLPG1690, which has completed Phase 1 clinical trial for the treatment of idiopathic pulmonary fibrosis. It is also developing GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; MOR106, which is in pre-clinical stage for the treatment of inflammatory diseases; and GLPG2665, a pre-clinical candidate for cystic fibrosis. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; with Servier to develop GLPG1972; and with AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium. http://www.priceseries.com/trade/GLPG-Galapagos-NV-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2017081020170921.html